Compare Novartis AG (NVS) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vale SA — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Vale SA trades at $13.63 (market cap $57.32B). The key difference: Novartis AG is far larger — about 4.7× Vale SA's market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vale SA for 109 Days on average.
| NVS | VALE | |
|---|---|---|
Market Cap | $268.57B | $57.32B |
Volume | 1,532,573 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $17.82 |
52-Week Low | $121.80 | $10.75 |
Typical Hold Time | 82 Days | 109 Days |
Enterprise Value | $309.89B | $73.56B |
Dividend Yield | 3.31% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
VALE trades at $13.62, near recent lows, with a bearish technical outlook and mixed sentiment. The stock has missed earnings expectations in recent quarters, with Q3 2026 EPS expected at $0.4212. Revenue has declined from $43.8B in 2022 to $38.4B in 2025, though 2026 is projected at $41.2B. Net income margin compressed to 5.11% in 2025. Analyst consensus is a 'Hold' with a $16.21 price target, indicating modest upside potential from current levels.
VALE faces headwinds from cyclical commodity exposure and cost inflation, but its base metals segment shows growth. Investment appeal hinges on iron ore price stability and execution on cost controls. Risks include regulatory challenges in Brazil and volatile raw material markets. The stock offers a dividend yield but requires careful monitoring of earnings trajectory and macroeconomic factors affecting mining sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
